
Atorvastatin improved kidney function dose-dependently across 6 RCTs with 30,621 patients
Louis cites a JAHA post hoc analysis of six double-blind outcome trials in patients at risk of or with cardiovascular disease. Atorvastatin improved kidney function over time in a dose-dependent way, and improvement in kidney function was associated with lower cardiovascular risk. The authors suggest kidney function could serve as a surrogate end point.